Browsing Tag
MannKind Corporation
3 posts
Furoscix ReadyFlow approval triggers $45m bill as MannKind Corporation raises fresh capital
MannKind Corporation wins Furoscix ReadyFlow approval and raises $50 million as a $45 million acquisition payment reshapes the outlook.
Could pediatric diabetes demand unlock new commercial momentum for MannKind Corporation’s Afrezza?
Find out how Afrezza’s pediatric FDA approval could strengthen MannKind’s growth story and reshape investor sentiment today.
Biotech shake-up: can Dr. Ajay Ahuja’s appointment as CMO mark a turning point for MannKind?
Find out why MannKind (Nasdaq: MNKD) appointed Dr. Ajay Ahuja as chief medical officer and what this means for its pipeline and stock outlook.